Bright Path Laboratories, Inc. (BPL), a provider of continuous flow reactor technology, was accepted into the FDA’s Emerging Technology Program, paving the way for the company to provide its low-cost and scalable technology to the domestic API manufacturing sector.  The Emerging Technology Program was created to help promote the adoption of innovative approaches to pharmaceutical product design and manufacturing and allows private companies the opportunity to discuss, identify, and res...